

Appln. No. 09/700,879

Amd. dated October 15, 2003

Reply to Office Action of July 15, 2003

**REMARKS**

The Office Action and cited and applied references have been carefully reviewed. No claim is allowed. Claims 1, 3, 5-12, and 17-25 presently appear in this application and define patentable subject matter warranting their allowance.

Reconsideration and allowance are hereby respectfully solicited.

New claim 25 is added and the recited features are supported in the specification on page 12, lines 20-22 and by original claim 14.

Claim 9 has been rejected under 35 U.S.C. §112, second paragraph, as being indefinite. This rejection is obviated by changing the dependency of claim 9 from claim 1 to claim 3 as helpfully suggested by the examiner.

Claims 1, 8, 11-14, 19, 23, and 24 have been rejected under 35 U.S.C. §102(b) as being anticipated by Sakurai et al. (ref. U1). The examiner states that Sakurai teaches a conjugate of superoxide dismutase and sodium hyaluronate in which the two moieties are covalently linked by a spacer. This rejection is respectfully traversed.

Contrary to the examiner's assertion, the superoxide dismutase (SOD) in the conjugate taught by Sakurai is bound directly to sodium hyaluronate without a spacer. The disclosure in Sakurai of "Conjugation of SOD with sodium hyaluronate" on page 724 shows a reaction of superoxide dismutase with sodium

Appln. No. 09/700,879  
Amd. dated October 15, 2003  
Reply to Office Action of July 15, 2003

hyaluronate using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. 1-Ethyl-3-(3-dimethyl aminopropyl) carbodiimide is a catalyst for condensation of carboxylic acids such as sodium hyaluronate with amines such as SOD. It functions by activating the free carboxylic acid of sodium hyaluronate. Attached hereto is page 948 from the reference text, Streitweiser and Heathcock, Introduction to Organic Chemistry, Third Edition, which presents a scheme showing a reaction of carboxylic acid with an amine using a carbodiimide represented by  $R'N=C=NR'$ . In the scheme, the intermediate O-acylisourea, which was prepared by reacting the carboxylic acid with the carbodiimide, is shown as an activated carboxylic acid derivative. Nucleophilic substitution of the O-acylisourea by the amine yields the amide and the dialkylurea.

As is clear from the reaction scheme attached hereto, the product of the reaction disclosed in Sakurai is an amide in which amino groups of SOD are directly coupled with carboxylic acid of sodium hyaluronate with no spacer involved. Accordingly, Sakurai cannot anticipate the presently claimed invention where a therapeutic agent for joint diseases is covalently bound to hyaluronic acid via a spacer.

Reconsideration and withdrawal of the rejection are therefore respectfully requested.

Appln. No. 09/700,879  
Amd. dated October 15, 2003  
Reply to Office Action of July 15, 2003

The examiner has rejected the present claims under 35 U.S.C. §103(a) as being unpatentable over Sakurai as the primary reference in view of one or more secondary references cited and applied in the previous Office Action of February 14, 2003, Paper No. 7, and selected from Gallardy (WO 92/09556), Falk (U.S. Patent 5,910,489), Bemis (U.S. Patent 6,147,080), and Wunderlich (U.S. Patent 6,066,332). The §103(a) rejections are respectfully traversed.

The examiner has acknowledged on page 3 of the present Office Action that the references as applied in the previous Office Action, which include all the secondary references cited and applied in the present Office Action, do not teach or suggest conjugates wherein the therapeutic agent and the hyaluronic acid are covalently bound to each other via a spacer. Therefore, none of the secondary cited and applied references taken alone or in combination with Sakurai and/or with each other can lead one of ordinary skill in the art to the presently claimed invention, given the deficiency in Sakurai as discussed above with regard to the §102(b) rejection.

Furthermore, the conjugate of the present invention has effective pharmacological properties such that the conjugate can be retained in the form of a conjugate at the target site (i.e., a joint cavity) for a long period of time and can exhibit both (1) MMP inhibition as inhibiting the destruction of cartilage

Appln. No. 09/700,879  
Amd. dated October 15, 2003  
Reply to Office Action of July 15, 2003

matrix and (2) the medical effect of hyaluronic acids as alleviating the disorder of joint functions by acting as a lubricant, with enhancement of the hyaluronic acid production in joints. See specification at page 5, lines 4-7 and page 7, line 26 to page 8, line 10. The synergistic effects of the presently claimed conjugate as a result of a covalent bond between a therapeutic agent and hyaluronic acid via a spacer is certainly unexpected.


Reconsideration and withdrawal of all the §103(a) rejections are therefore respectfully requested.

In view of the above, the claims comply with 35 U.S.C. 112 and define patentable subject matter warranting their allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

A handwritten signature in black ink, appearing to be 'A. Yun', is written over a horizontal line.

Allen C. Yun  
Registration No. 37,971

ACY:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\Y\YUAS\Tamura 5\PTO\amd OA 7-15-03.doc

*THIRD EDITION*

---

# Introduction to Organic Chemistry

---

*Andrew Streitwieser, Jr.*

*Clayton H. Heathcock*

*UNIVERSITY OF CALIFORNIA, BERKELEY*



*Macmillan Publishing Company*    *New York*

*Collier Macmillan Publishers*    *London*


---

$$\text{RCOH} + \text{RN}=\text{C}=\text{NR}' \longrightarrow \text{R}-\overset{\text{O}}{\underset{\text{O}}{\text{C}}}-\text{O}-\overset{\text{NHR}'}{\underset{\text{N}}{\text{C}}}=\text{NR}'$$


an O-acylisourea

$$\text{RC(=O)-O-C(=NR')NHR'} + \text{R''NH}_2 \rightleftharpoons \left[ \text{RC(=NR')NHR''-O-C(=NR')NHR'} \right] \rightleftharpoons \left[ \text{RC(=NR')NHR''-O-C(=NR')NHR'} \right] \rightarrow \text{RC(=O)NHR''} + \text{R'NHC(=O)NHR'}$$
$$\begin{array}{c} \text{CbzNHCHCOOH} \\ | \\ \text{CHOH} \\ | \\ \text{CH}_3 \\ \text{N-protected threonine} \end{array} + \begin{array}{c} \text{H}_2\text{NCHCOOCH}_2\text{C}_6\text{H}_5 \\ | \\ \text{CH}_3 \\ \text{C-protected alanine} \end{array} \xrightarrow{\text{DCC}} \begin{array}{c} \text{CbzNHCH} \overset{\text{O}}{\parallel} \text{CNHCHCOOCH}_2\text{C}_6\text{H}_5 \\ | \qquad \qquad | \\ \text{CHOH} \qquad \text{CH}_3 \\ | \qquad \qquad | \\ \text{CH}_3 \qquad \qquad \text{Cbz-Thr-Ala-CH}_2\text{C}_6\text{H}_5 \end{array} \xrightarrow[\text{HOAc}]{\text{H}_2\text{-Pd/C}}$$
[NH3+]CCCCNC(=O)OCC1=CC=CC=C1C(=O)[O-]  
 ε-benzoyloxycarbonyllysine


A recent development in the technique introduced by Kunitz and co-workers received the 1984 Nobel Prize. The protein is synthesized in a cell-free system, soluble and can be reprecipitated in a medium in which some of the amino acids are replaced by fluorescent amino acids. The rene used is cross-linked by formaldehyde from 20 to 70  $\mu$ m.




Typically, about 10% of the C-terminal residues of the insoluble polypeptide are removed by treatment with a solvent such as 10% TFA. The ester is the



Excess reagents  
washed and the



A solution of an  
ous mixture is :



The polymer, 1